Compare ENTA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | AVXL |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 430.9M |
| IPO Year | 2012 | 2013 |
| Metric | ENTA | AVXL |
|---|---|---|
| Price | $12.12 | $4.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $20.40 | ★ $22.00 |
| AVG Volume (30 Days) | 147.1K | ★ 964.1K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.09 | $2.86 |
| 52 Week High | $17.15 | $13.99 |
| Indicator | ENTA | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 25.24 |
| Support Level | $12.09 | N/A |
| Resistance Level | $15.52 | $4.98 |
| Average True Range (ATR) | 0.63 | 0.26 |
| MACD | -0.17 | -0.13 |
| Stochastic Oscillator | 7.62 | 2.51 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.